Table 4.

Factors associated with use of ART and HIV virologic suppression

Characteristic	Use of ART AOR (95 % CI)	HIV viral suppression AOR (95 % CI)
No. of clinics visited per year
1	1.00 (Ref)	1.00 (Ref)
≥2	0.62 (0.55–0.71)	0.78 (0.66–0.94)
Age (years)
18–29	1.00 (Ref)	1.00 (Ref)
30–39	1.67 (1.48–1.88)	1.53 (1.33–1.76)
40–49	2.44 (2.18–2.73)	1.85 (1.63–2.11)
≥50	2.80 (2.47–3.18)	2.64 (2.30–3.04)
Sex
Male	1.00 (Ref)	1.00 (Ref)
Female	0.86 (0.77–0.95)	0.85 (0.77–0.94)
Race/ethnicity
White	1.00 (Ref)	1.00 (Ref)
Black	0.97 (0.87–1.09)	0.69 (0.61–0.78)
Hispanic	1.07 (0.92–1.24)	0.96 (0.82–1.12)
Other/unknown	0.75 (0.62–0.91)	0.92 (0.73–1.16)
HIV risk factor
Heterosexual	1.00 (Ref)	1.00 (Ref)
MSM	0.97 (0.86–1.08)	1.23 (1.10–1.38)
IDU	0.92 (0.81–1.04)	0.81 (0.73–0.91)
Other/unknown	0.78 (0.66–0.92)	0.97 (0.80–1.16)
Insurance
Private	1.00 (Ref)	1.00 (Ref)
Medicaid	1.10 (0.98–1.23)	0.69 (0.61–0.79)
Medicare	1.27 (1.10–1.47)	0.73 (0.63–0.85)
Ryan white/uninsured	0.73 (0.65–0.83)	0.67 (0.58–0.78)
Other/unknown	0.60 (0.48–0.76)	0.71 (0.50–1.01)
Income ($)
<10,000	1.00 (Ref)	1.00 (Ref)
10,000–19,999	1.06 (0.97–1.16)	1.08 (0.98–1.18)
20,000–49,999	0.99 (0.88–1.12)	1.34 (1.15–1.55)
≥50,000	1.32 (1.00–1.73)	1.40 (1.01–1.93)
Median CD4 cell count (cell/mm3)
≤350	1.00 (Ref)	1.00 (Ref)
>350	0.58 (0.53–0.63)	4.30 (3.98–4.64)
First year in care
No	1.00 (Ref)	1.00 (Ref)
Yes	0.39 (0.36–0.42)	0.77 (0.70–0.85)
No. of primary HIV visits per year
2	1.00 (Ref)	1.00 (Ref)
3	1.20 (1.10–1.32)	1.13 (1.00–1.27)
4	1.50 (1.36–1.65)	1.30 (1.15–1.47)
5	1.62 (1.46–1.80)	1.46 (1.28–1.66)
6	1.62 (1.45–1.82)	1.57 (1.36–1.80)
7	2.10 (1.83–2.40)	1.61 (1.38–1.87)
≥8	1.95 (1.76–2.16)	1.51 (1.35–1.70)
Year
2008	1.00 (Ref)	1.00 (Ref)
2009	1.23 (1.15–1.30)	1.25 (1.16–1.35)
2010	1.38 (1.29–1.47)	1.48 (1.37–1.60)

AOR adjusted odds ratio, ART antiretroviral therapy, HET heterosexual transmission, HIV human immunodeficiency virus, IDU injection drug use, MSM men who have sex with men